Perthera company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

perthera.com

Founded Year

2012

Stage

Convertible Note | Alive

Total Raised

$20.24M

Last Raised

$500K | 4 mos ago

Revenue

$0000 

About Perthera

Perthera uses AI to analyze patient medical and molecular data to enable hospitals, physicians & advocacy groups to deliver personalized cancer care. The Perthera Platform matches patients to ranked therapeutic options to improve their clinical outcomes and allows patient data access to the key segments in the Precision Oncology market. It was founded in 2012 and is based in McLean, Virginia.

Perthera Headquarter Location

8200 Greensboro Dr. Suite 350

McLean, Virginia, 22102,

United States

508-909-5100

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Perthera

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Perthera is included in 8 Expert Collections, including Artificial Intelligence.

A

Artificial Intelligence

9,093 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

M

Medical Devices

8,442 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

13,075 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Perthera Patents

Perthera has filed 6 patents.

The 3 most popular patent topics include:

  • Genetics
  • Graphical control elements
  • Graphical user interface elements
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/28/2017

6/18/2019

Graphical user interface elements, Graphical user interfaces, Graphical control elements, Graphical user interface testing, User interfaces

Grant

Application Date

6/28/2017

Grant Date

6/18/2019

Title

Related Topics

Graphical user interface elements, Graphical user interfaces, Graphical control elements, Graphical user interface testing, User interfaces

Status

Grant

Latest Perthera News

PERTHERA AND SIDE-OUT FOUNDATION ANNOUNCE INNOVATIVE CLINICAL PARTNERSHIP

May 20, 2021

DELIVERING PRECISION MEDICINE TO ADVANCED BREAST CANCER PATIENTS ACROSS THE NATION HOLLISTON , MASSACHUSETTS , UNITED STATES , May 20, 2021 / EINPresswire.com / — Perthera, a market leader in Precision Oncology, and The Side-Out Foundation, a not-for-profit organization focused on advancing clinical research in breast cancer, have forged a comprehensive partnership to deliver precision medicine and personalized treatment recommendations to physicians and patients throughout the country. Together, Perthera and Side-Out are launching a national clinical study program to improve outcomes for patients with advanced breast cancer, demonstrate the impact of precision oncology and accelerate clinical trial enrollment across the nation, to advance medicine & science through groundbreaking research publications. “We are excited to partner with Perthera on this initiative and are confident it will have a dramatic impact on breast cancer care for patients, now and long into the future,” said Rick Dunetz, Executive Director of Side-Out. “With combined efforts spanning over a decade of work in precision medicine research and focused breast cancer research between our organizations, this will be a strong partnership to make a difference in advanced breast cancer management. Perthera’s Multiomic Precision Oncology Analysis is clinically proven to increase both overall survival and progression-free survival for patients receiving precisely matched, personalized treatment recommendations. Perthera’s Platform also delivers a best-in-class ability to expand clinical trial enrollment and seamlessly capture comprehensive patient outcomes to advance clinical research. Through these innovative capabilities, we aim to advance care for breast cancer patients today and for future patients through our contributions to medicine and science.” Funded through Side-Out’s philanthropic support, all patients who have been molecularly profiled or who have upcoming testing can be enrolled in the program, regardless of geographical location or insurance status. Perthera’s highly trained clinical team will coordinate everything for each patient to ensure they can receive the testing required to advance their care and participate in the program. Patients, their oncologists and care teams, will be provided with significant resources, including Perthera’s precisely matched treatment recommendations proven to increase survival, clinical trial matching services shown to increase enrollment at 5X the national average, and Side-Out’s economic support to ensure patients receive these resources regardless of barriers. This program will capture highly comprehensive patient outcomes for utilization in research and publications to benefit breast cancer patients worldwide. “We are highly enthused to be launching this Program with a leading breast cancer research organization such as The Side-Out Foundation. Which has advanced clinical trials and research for breast cancer patients for over a decade,” said Gary Gregory, CEO of Perthera. “Together, through our patient-centric clinical study designed to benefit more than thousand patients across the nation. Not only will we deliver our decision support and clinical trial matching to oncologists and patients, but through our outcomes capturing capabilities, we aim to build one of the world’s most comprehensive, breast cancer, Real World Evidence database. Side-Out’s leadership and mission is focused on patient driven research and the results of that research. They are partnering with Perthera to realize their vision by our harnessing the power of medicine, science and data, which will undoubtedly drive this program to be a resounding success.” Media Contacts: About the Side-Out Foundation The Side-Out Foundation is a not-for -profit organization that was established in 2004 to make a significant and identifiable impact on the lives of metastatic breast cancer patients and their families. Side-Out’s precision medicine research matches patients with treatments and uses the outcome data produced from this to draw conclusions, challenge the standard level of care, and change the trajectory of the disease. Since its inception, Side-Out has raised over $10 million for its proprietary clinical trials through unique and creative grass roots programs in the sport of volleyball with educational and community-driven events such as Dig Pink® and the Side-Out Ambassador Program, creating advocacy for the metastatic breast cancer community. About Perthera Perthera is a leading Precision Oncology Company advancing cancer care through our Precision Medicine Platform. Our innovative technology precisely matches cancer patients with ranked treatment recommendations and has been utilized by over 250 US healthcare sites and by more than 10% of all oncologists. We have developed a turnkey Precision Oncology Platform with an AI-driven Intelligence Engine, which has been clinically proven to extend cancer patients’ overall survival rates by over a year and progression-free survival rates by a factor of 2.4X. Perthera positions hospitals and physicians to deliver best-in-class cancer care to improve patient outcomes and save lives without altering their current clinical practices, patient flow, or lab preferences. The Perthera Platform also offers a highly comprehensive Precision Cancer Database and well-curated Real-World-Data, which delivers significant value to BioPharma (Pharma, Biotech, Drug Development, and Clinical Research Organizations). Safe Harbor Statement: The statements in the press release that relate to Perthera, Inc. (the “Company”) expectations regarding the future impact on the Company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties which could cause the Company's actual operating results, performance, business plans or prospects to differ materially from those expressed in or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events. Gary L. Gregory

Perthera Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Perthera Rank

  • When was Perthera founded?

    Perthera was founded in 2012.

  • Where is Perthera's headquarters?

    Perthera's headquarters is located at 8200 Greensboro Dr., McLean.

  • What is Perthera's latest funding round?

    Perthera's latest funding round is Convertible Note.

  • How much did Perthera raise?

    Perthera raised a total of $20.24M.

  • Who are the investors of Perthera?

    Investors of Perthera include Pilot Growth Equity and McLean Capital.

  • Who are Perthera's competitors?

    Competitors of Perthera include Massive Bio, OmniSeq, Caris Life Sciences, CureMatch, Tempus and 7 more.

You May Also Like

Strata Oncology Logo
Strata Oncology

Strata Oncology is a precision medicine company that provides no-cost tumor sequencing to advanced cancer patients and a portfolio of matching clinical trials.

F
First Ascent Biomedical

First Ascent Biomedical develops personalized cancer treatment plans based on the biology of patients’ tumors and the response to multi-drug combinations, using individual DNA, RNA, and AI to pick the compounds that are most effective in treating an individual.

Evidation Logo
Evidation

Evidation measures health in everyday life and enables anyone to participate in research and health programs. Evidation is a two-sided platform that connects individuals and enterprises. On the consumer side, the company assists individuals to participate in research including testing of digital health programs. On the enterprise side, Evidation provides biopharma, med-tech, big tech, academic institutions, professional societies, and government partners the ability to: generate evidence; and design, test, and deploy programs that motivate evidence-based action.

Deep Lens Logo
Deep Lens

Deep Lens is an AI company focused on identifying patients for clinical trials using VIPER, an AI-driven, digital pathology cloud platform which for over ten years has allowed pathology groups to collaborate on groundbreaking cancer research across dozens of cancer types.

Protean BioDiagnostics Logo
Protean BioDiagnostics

Protean BioDiagnostics is committed to creating and deploying laboratory diagnostic tools to support physicians.

Syapse Logo
Syapse

Syapse develops applications that enable the use of omics profiles in diagnosing and treating patients at diagnostic companies, research institutions, medical centers, and payers. The Syapse Discovery application provides an end-to-end solution for companies and laboratories deploying sequencing-based diagnostics, from patient sample received to physician report delivered. Discovery's configurable semantic data structure enables users to bring omics data together with traditional medical information to develop and deliver diagnostic tests. The platform's open interfaces enable bioinformaticians and biologists to use their favorite computational tools and annotations. The company was formerly known as BDLicense. Syapse was founded in 2008 and is based in San Francisco, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.